logo-loader
RNS
viewAlliance Pharma PLC

Alliance Pharma PLC - Director Share Purchases

RNS Number : 2849R
Alliance Pharma PLC
26 June 2020
 

 

 

                                             26 June 2020

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Director Share Purchases

 

Alliance Pharma plc (AIM: APH), the international healthcare group, was notified on 23 June 2020 that on 23 June 2020 David Cook, Chairman of the Company, purchased 63,879 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 77.7 pence per share, and his spouse, Katharine Cook, also purchased 63,879 Ordinary Shares on the same date at 77.7 pence per share.

 

Following these transactions, David and Katharine Cook's total beneficial interest in the Company is 234,129 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital.

 

The notification of dealing forms for Persons Discharging Managerial Responsibility ("PDMR") and Person Closely Associated ("PCA") can be found below. The information contained within this announcement is made in accordance with the requirements of the EU Market Abuse Regulation.

  

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

David Cook

2

Reason for the notification

a)

Position/status

Non-Executive Chairman, PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma Plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 

 

 

GB0031030819

 

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

 

d)

Price(s) and volume(s)

Price(s)

Volume(s)

77.7p

63,879

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 n/a

 

f)

Date of the transaction

23 June 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Katharine Cook

2

Reason for the notification

a)

Position/status

PCA with David Cook, Chairman and PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma Plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 

 

 

GB0031030819

 

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

 

d)

Price(s) and volume(s)

Price(s)

Volume(s)

77.7p

63,879

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 n/a

 

f)

Date of the transaction

23 June 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

For further information:

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / Tejas Padalkar

 

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHSEFFWMESSEFM

Quick facts: Alliance Pharma PLC

Price: 71.9

Market: AIM
Market Cap: £381.84 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE